Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986196 DDI with Oral Contraceptives
NCT05891262Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2023
- Primary completion
- Aug 2023
- Modality
- Irreversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of 11c-bms-986196 in multiple sclerosis (MS), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration at Day 20, Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration at Day 20 and 1 more. Started Jun 2023; status: completed.
02
Drugs
11c-bms-986196
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05891262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05891262.